Published in FEBS J on June 01, 2006
Amyloid beta-protein dimers rapidly form stable synaptotoxic protofibrils. J Neurosci (2010) 1.92
Abeta42 mutants with different aggregation profiles induce distinct pathologies in Drosophila. PLoS One (2008) 1.46
Competitive Mirror Image Phage Display Derived Peptide Modulates Amyloid Beta Aggregation and Toxicity. PLoS One (2016) 1.40
Amyloid-beta protofibril levels correlate with spatial learning in Arctic Alzheimer's disease transgenic mice. FEBS J (2009) 1.08
Tau oligomers impair artificial membrane integrity and cellular viability. J Biol Chem (2012) 1.03
Sensitive detection of Aβ protofibrils by proximity ligation--relevance for Alzheimer's disease. BMC Neurosci (2010) 1.02
Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer's disease. Alzheimers Res Ther (2014) 1.00
A novel inhibitor of amyloid β (Aβ) peptide aggregation: from high throughput screening to efficacy in an animal model of Alzheimer disease. J Biol Chem (2012) 0.98
Transgenic Drosophila models of Alzheimer's disease and tauopathies. Brain Struct Funct (2009) 0.96
Recombinant amyloid beta-peptide production by coexpression with an affibody ligand. BMC Biotechnol (2008) 0.90
Intracellular amyloid formation in muscle cells of Abeta-transgenic Caenorhabditis elegans: determinants and physiological role in copper detoxification. Mol Neurodegener (2009) 0.86
Observations in APP bitransgenic mice suggest that diffuse and compact plaques form via independent processes in Alzheimer's disease. Am J Pathol (2011) 0.86
The CCAAT/enhancer binding protein (C/EBP) δ is differently regulated by fibrillar and oligomeric forms of the Alzheimer amyloid-β peptide. J Neuroinflammation (2011) 0.84
Immobilization of homogeneous monomeric, oligomeric and fibrillar Aβ species for reliable SPR measurements. PLoS One (2014) 0.83
QIAD assay for quantitating a compound's efficacy in elimination of toxic Aβ oligomers. Sci Rep (2015) 0.82
Structural Polymorphism of Alzheimer's β-Amyloid Fibrils as Controlled by an E22 Switch: A Solid-State NMR Study. J Am Chem Soc (2016) 0.81
On the stability of the soluble amyloid aggregates. Biophys J (2009) 0.80
Genetic animal models of cerebral vasculopathies. Prog Mol Biol Transl Sci (2012) 0.79
Characterization of a single-chain variable fragment recognizing a linear epitope of aβ: a biotechnical tool for studies on Alzheimer's disease? PLoS One (2013) 0.79
Aβ peptide fibrillar architectures controlled by conformational constraints of the monomer. PLoS One (2011) 0.77
Point mutations in Aβ induce polymorphic aggregates at liquid/solid interfaces. ACS Chem Neurosci (2011) 0.76
Tailoring the antibody response to aggregated Aß using novel Alzheimer-vaccines. PLoS One (2015) 0.76
Influence of gold nanoparticle surface chemistry and diameter upon Alzheimer's disease amyloid-β protein aggregation. J Biol Eng (2017) 0.75
Ion Channel Formation by Amyloid-β42 Oligomers but not Amyloid-β40 in Cellular Membranes. J Biol Chem (2016) 0.75
A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. Nat Genet (2012) 4.37
Nonmyelinating Schwann cells maintain hematopoietic stem cell hibernation in the bone marrow niche. Cell (2011) 4.04
Signaling pathways governing stem-cell fate. Blood (2007) 2.38
Imaging distinct conformational states of amyloid-beta fibrils in Alzheimer's disease using novel luminescent probes. ACS Chem Biol (2007) 2.18
Age-related somatic structural changes in the nuclear genome of human blood cells. Am J Hum Genet (2012) 2.15
Measurement of alpha- and beta-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients. Exp Neurol (2003) 1.99
Hematopoietic stem cell responsiveness to exogenous signals is limited by caspase-3. Cell Stem Cell (2008) 1.94
Stabilization of neurotoxic Alzheimer amyloid-beta oligomers by protein engineering. Proc Natl Acad Sci U S A (2010) 1.72
PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses. J Alzheimers Dis (2010) 1.57
Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: relating plasma circulation lifetimes to protein binding. Biochim Biophys Acta (2007) 1.56
Longitudinal stability of CSF biomarkers in Alzheimer's disease. Neurosci Lett (2007) 1.54
The Arctic Alzheimer mutation facilitates early intraneuronal Abeta aggregation and senile plaque formation in transgenic mice. Neurobiol Aging (2005) 1.53
Cripto regulates hematopoietic stem cells as a hypoxic-niche-related factor through cell surface receptor GRP78. Cell Stem Cell (2011) 1.47
Sensitive ELISA detection of amyloid-beta protofibrils in biological samples. J Neurochem (2007) 1.46
Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population-based cohort study. Arch Neurol (2008) 1.46
Amyloid-beta oligomers are inefficiently measured by enzyme-linked immunosorbent assay. Ann Neurol (2005) 1.45
Complex and context dependent regulation of hematopoiesis by TGF-beta superfamily signaling. Ann N Y Acad Sci (2009) 1.45
Liposomes, disks, and spherical micelles: aggregate structure in mixtures of gel phase phosphatidylcholines and poly(ethylene glycol)-phospholipids. Biophys J (2003) 1.43
No association between CALHM1 and Alzheimer's disease risk. Cell (2008) 1.30
In vivo amyloid imaging with PET in frontotemporal dementia. Eur J Nucl Med Mol Imaging (2007) 1.29
Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype. Dement Geriatr Cogn Disord (2009) 1.23
Identification of low molecular weight pyroglutamate A{beta} oligomers in Alzheimer disease: a novel tool for therapy and diagnosis. J Biol Chem (2010) 1.22
Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases. J Neural Transm (Vienna) (2009) 1.22
The CALHM1 P86L polymorphism is a genetic modifier of age at onset in Alzheimer's disease: a meta-analysis study. J Alzheimers Dis (2010) 1.19
Polymorphisms in the SCD1 gene: associations with body fat distribution and insulin sensitivity. Obesity (Silver Spring) (2007) 1.18
The common FTO variant rs9939609 is not associated with BMI in a longitudinal study on a cohort of Swedish men born 1920-1924. BMC Med Genet (2009) 1.16
Systemic inflammation and the risk of Alzheimer's disease and dementia: a prospective population-based study. J Alzheimers Dis (2009) 1.12
Direct observation and characterization of DMPC/DHPC aggregates under conditions relevant for biological solution NMR. Biochim Biophys Acta (2004) 1.12
Loss of astrocyte polarization in the tg-ArcSwe mouse model of Alzheimer's disease. J Alzheimers Dis (2011) 1.11
The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer's disease. Neurosci Lett (2007) 1.09
Amyloid-beta protofibril levels correlate with spatial learning in Arctic Alzheimer's disease transgenic mice. FEBS J (2009) 1.08
Animal models of amyloid-beta-related pathologies in Alzheimer's disease. FEBS J (2010) 1.06
An amyloid-beta protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease. Neurobiol Dis (2009) 1.06
Identification of novel biomarker candidates by differential peptidomics analysis of cerebrospinal fluid in Alzheimer's disease. Comb Chem High Throughput Screen (2005) 1.04
Heparan sulfate mediates amyloid-beta internalization and cytotoxicity. Glycobiology (2010) 1.04
Assembly and structural analysis of a covalently closed nano-scale DNA cage. Nucleic Acids Res (2007) 1.04
Therapeutically optimized rates of drug release can be achieved by varying the drug-to-lipid ratio in liposomal vincristine formulations. Biochim Biophys Acta (2006) 1.04
Pen-2 is sequestered in the endoplasmic reticulum and subjected to ubiquitylation and proteasome-mediated degradation in the absence of presenilin. J Biol Chem (2004) 1.03
Self-assembly of beta-cyclodextrin in water. Part 1: Cryo-TEM and dynamic and static light scattering. Langmuir (2006) 1.03
The lipid peroxidation products 4-oxo-2-nonenal and 4-hydroxy-2-nonenal promote the formation of α-synuclein oligomers with distinct biochemical, morphological, and functional properties. Free Radic Biol Med (2010) 1.03
Genetic analysis of Alzheimer's disease in the Uppsala Longitudinal Study of Adult Men. Dement Geriatr Cogn Disord (2009) 1.02
The Arctic Alzheimer mutation favors intracellular amyloid-beta production by making amyloid precursor protein less available to alpha-secretase. J Neurochem (2007) 1.02
A highly insoluble state of Abeta similar to that of Alzheimer's disease brain is found in Arctic APP transgenic mice. Neurobiol Aging (2008) 1.02
Sensitive detection of Aβ protofibrils by proximity ligation--relevance for Alzheimer's disease. BMC Neurosci (2010) 1.02
Dynamic analysis of gene expression and genome-wide transcription factor binding during lineage specification of multipotent progenitors. Cell Stem Cell (2013) 1.01
Extracellular alpha-synuclein oligomers modulate synaptic transmission and impair LTP via NMDA-receptor activation. J Neurosci (2012) 1.01
Formation of transition metal-doxorubicin complexes inside liposomes. Biochim Biophys Acta (2002) 1.00
Extended investigation of tau and mutation screening of other candidate genes on chromosome 17q21 in a Swedish FTDP-17 family. Am J Med Genet B Neuropsychiatr Genet (2003) 0.99
Effect of lipid headgroup composition on the interaction between melittin and lipid bilayers. J Colloid Interface Sci (2007) 0.99
Development of EGF-conjugated liposomes for targeted delivery of boronated DNA-binding agents. Bioconjug Chem (2002) 0.99
Clinical and neuropathological features of the arctic APP gene mutation causing early-onset Alzheimer disease. Arch Neurol (2008) 0.98
Vascular risk factors and dementia: 40-year follow-up of a population-based cohort. Dement Geriatr Cogn Disord (2011) 0.97
The tau R406W mutation causes progressive presenile dementia with bitemporal atrophy. Dement Geriatr Cogn Disord (2004) 0.97
Population-based study of non-infectious rhinitis in relation to occupational exposure, age, sex, and smoking. Am J Ind Med (2002) 0.97
Oligomerization partially explains the lowering of Abeta42 in Alzheimer's disease cerebrospinal fluid. Neurodegener Dis (2009) 0.97
Microglial markers are elevated in the prodromal phase of Alzheimer's disease and vascular dementia. J Alzheimers Dis (2013) 0.97
Heparan sulfate accumulation with Abeta deposits in Alzheimer's disease and Tg2576 mice is contributed by glial cells. Brain Pathol (2008) 0.97
Increase in beta-amyloid levels in cerebrospinal fluid of children with Down syndrome. Dement Geriatr Cogn Disord (2007) 0.96
Neurofilament ELISA validation. J Immunol Methods (2009) 0.96
Large aggregates are the major soluble Aβ species in AD brain fractionated with density gradient ultracentrifugation. PLoS One (2012) 0.96
The fat mass and obesity gene is linked to reduced verbal fluency in overweight and obese elderly men. Neurobiol Aging (2011) 0.95
pH gradient loading of anthracyclines into cholesterol-free liposomes: enhancing drug loading rates through use of ethanol. Biochim Biophys Acta (2004) 0.95
Glucose metabolism and PIB binding in carriers of a His163Tyr presenilin 1 mutation. Neurobiol Aging (2009) 0.95
Docosahexaenoic acid stabilizes soluble amyloid-beta protofibrils and sustains amyloid-beta-induced neurotoxicity in vitro. FEBS J (2007) 0.94
Interference from heterophilic antibodies in amyloid-β oligomer ELISAs. J Alzheimers Dis (2010) 0.94
All-or-none membrane permeabilization by fengycin-type lipopeptides from Bacillus subtilis QST713. Biochim Biophys Acta (2011) 0.94
Novel findings in Swedish patients with MYH-associated polyposis: mutation detection and clinical characterization. Clin Gastroenterol Hepatol (2006) 0.93
Optimization and characterization of a sphingomyelin/cholesterol liposome formulation of vinorelbine with promising antitumor activity. J Pharm Sci (2005) 0.92
Association study of cholesterol-related genes in Alzheimer's disease. Neurogenetics (2007) 0.92
Formation of drug-arylsulfonate complexes inside liposomes: a novel approach to improve drug retention. J Control Release (2005) 0.91
Interactions between pH-sensitive liposomes and model membranes. Biophys Chem (2003) 0.91
Docosahexaenoic acid stimulates non-amyloidogenic APP processing resulting in reduced Abeta levels in cellular models of Alzheimer's disease. Eur J Neurosci (2007) 0.91
Antibodies against alpha-synuclein reduce oligomerization in living cells. PLoS One (2011) 0.91
Effects of lipid segregation and lysolipid dissociation on drug release from thermosensitive liposomes. J Control Release (2005) 0.90
Transition metal-mediated liposomal encapsulation of irinotecan (CPT-11) stabilizes the drug in the therapeutically active lactone conformation. Pharm Res (2006) 0.90
Optimized in vitro and in vivo expression of proteorhodopsin: a seven-transmembrane proton pump. Protein Expr Purif (2007) 0.90
Higher cathepsin B levels in plasma in Alzheimer's disease compared to healthy controls. J Alzheimers Dis (2010) 0.88
Immunotherapy targeting α-synuclein, with relevance for future treatment of Parkinson's disease and other Lewy body disorders. Immunotherapy (2014) 0.88
Heparanase overexpression impairs inflammatory response and macrophage-mediated clearance of amyloid-β in murine brain. Acta Neuropathol (2012) 0.88
CALHM1 P86L polymorphism does not alter amyloid-beta or tau in cerebrospinal fluid. Neurosci Lett (2009) 0.88
Morphology of magnetically aligning DMPC/DHPC aggregates-perforated sheets, not disks. Langmuir (2006) 0.88
No alteration in tau exon 10 alternative splicing in tangle-bearing neurons of the Alzheimer's disease brain. Acta Neuropathol (2006) 0.88
Development of a liposomal nanoparticle formulation of 5-fluorouracil for parenteral administration: formulation design, pharmacokinetics and efficacy. J Control Release (2010) 0.87